Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 2;14(11):1398.
doi: 10.3390/biom14111398.

Resveratrol Inhibits Nucleosome Binding and Catalytic Activity of PARP1

Affiliations

Resveratrol Inhibits Nucleosome Binding and Catalytic Activity of PARP1

Daria O Koshkina et al. Biomolecules. .

Abstract

The natural polyphenol resveratrol is a biologically active compound that interacts with DNA and affects the activity of some nuclear enzymes. Its effect on the interaction between nucleosomes and poly(ADP-ribose) polymerase-1 (PARP1) and on the catalytic activity of PARP1 was studied using Western blotting, spectrophotometry, electrophoretic mobility shift assay, and single particle Förster resonance energy transfer microscopy. Resveratrol inhibited PARP1 activity at micro- and sub-micromolar concentrations, but the inhibitory effect decreased at higher concentrations due to the aggregation of the polyphenol. The inhibition of PARP1 by resveratrol was accompanied by its binding to the enzyme catalytic center and a subsequent decrease in PARP1 affinity to nucleosomal DNA. Concurrent binding of talazoparib to the substrate binding pocket of PARP1, which occurs in the presence of resveratrol, restores the interaction of PARP1 with nucleosomes, suggesting that the binding sites of resveratrol and talazoparib overlap. The data suggest that resveratrol can be classified as a natural inhibitor of PARP1.

Keywords: PARP1; Western blotting; absorption spectroscopy; gel-shift analysis; nucleosome; poly(ADP-ribose) polymerase-1; resveratrol; spFRET.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Effect of RSV on the interaction between PARP1 and nucleosomes and on PARP1 activity. (A) The experimental approach. Small pink and green circles show the positions of fluorescent labels Cy3 and Cy5 on the nucleosomal DNA. Different domains of PARP1 are shown in color to highlight the multidomain structure of the enzyme. (B) Western blotting analysis of the effect of RSV on the PARP1 activity. Antibodies to poly(ADP-ribose) chains were used to stain auto-PARylated PARP1 after nucleosome-activated reaction of PARylation in the mixture of nucleosomes (Nuc, 2 nM), PARP1 (40 nM), NAD+ (20 μM) and different concentrations of RSV. M: protein molecular weight markers. Similar data were obtained in three independent experiments. (C) Absorption spectra of RSV at different concentrations in an aqueous solution containing 25% dimethyl sulfoxide. The dashed line shows the RSV spectrum at 100 nM magnified ×10 times in intensity.
Figure 2
Figure 2
RSV reduces the binding of PARP1 to nucleosomes. (A) EPR profiles of nucleosomes (Nuc) and their complexes with PARP1 (40 nM) in the absence and presence of RSV (1, 10 and 100 μM). EPR profiles are presented as mean ± standard error of the mean (n = 3). (B) EMSA data for nucleosomes and nucleosome–PARP1 complexes in the absence and presence of RSV (1, 10, and 100 μM).
Figure 3
Figure 3
Effect of RSV and TAL on the interaction between PARP1 and nucleosomes. EPR profiles of nucleosomes (Nuc) and their complexes with PARP1 (40 nM) in the absence and presence of RSV (10 μM) and TAL (1 μM). EPR profiles are presented as mean ± standard error of the mean (n = 3). (A) PARP1 was pre-incubated with RSV and then incubated with nucleosomes and TAL. (B) PARP1 was pre-incubated with TAL and then incubated with nucleosomes and RSV.

Similar articles

References

    1. Marti J.M., Fernandez-Cortes M., Serrano-Saenz S., Zamudio-Martinez E., Delgado-Bellido D., Garcia-Diaz A., Oliver F.J. The Multifactorial Role of PARP-1 in Tumor Microenvironment. Cancers. 2020;12:739. doi: 10.3390/cancers12030739. - DOI - PMC - PubMed
    1. Fröhlich L.M., Villar-Miyar A., Heintze T., Sauer B., Schittek B. PARP1 Expression Predicts PARP Inhibitor Sensitivity and Correlates with Metastatic Potential and Overall Survival in Melanoma. Int. J. Cancer. 2024;155:203–210. doi: 10.1002/ijc.34947. - DOI - PubMed
    1. Murnyák B., Kouhsari M.C., Hershkovitch R., Kálmán B., Marko-Varga G., Klekner Á., Hortobágyi T. PARP1 Expression and Its Correlation with Survival Is Tumour Molecular Subtype Dependent in Glioblastoma. Oncotarget. 2017;8:46348–46362. doi: 10.18632/oncotarget.18013. - DOI - PMC - PubMed
    1. Rojo F., García-Parra J., Zazo S., Tusquets I., Ferrer-Lozano J., Menendez S., Eroles P., Chamizo C., Servitja S., Ramírez-Merino N., et al. Nuclear PARP-1 Protein Overexpression Is Associated with Poor Overall Survival in Early Breast Cancer. Ann. Oncol. 2012;23:1156–1164. doi: 10.1093/annonc/mdr361. - DOI - PubMed
    1. Qiao W., Pan L., Kou C., Li K., Yang M. Prognostic and Clinicopathological Value of Poly (Adenosine Diphosphate-Ribose) Polymerase Expression in Breast Cancer: A Meta-Analysis. PLoS ONE. 2017;12:e0172413. doi: 10.1371/journal.pone.0172413. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources